MENU
Home
Add Document
Sign In
Create An Account
PDF Reader
Full Text
Suggest Documents
Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
Association of the Co-stimulatory Molecules Polymorphisms with CMV Infection in Liver Transplant Recipients.
Adenovirus infection in pediatric liver transplant recipients.
Clinical significance of surveillance culture in liver transplant recipients.
Search continues for a CMV vaccine for transplant recipients.
Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
Different behaviour of BK-virus infection in liver transplant recipients.
Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.
Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients.
Hepatitis C viral infection in liver transplant recipients.
Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET).
Surgical wound infection by Aspergillus fumigatus in liver transplant recipients.
The management of T tube leaks in orthotopic liver transplant recipients with endoscopically placed nasobiliary catheters.
Lipids in liver transplant recipients.
Boceprevir in liver transplant recipients.
Screening HIV-infected recipients of blood transfusions for CMV infection.
Cytomegalovirus infection in transplant recipients.
Surveillance and treatment of liver transplant recipients for candidiasis and aspergillosis.
When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?
Liver biopsy-related infection in liver transplant recipients: A current matter of concern?
Risk factors for mortality in liver transplant recipients with ESKAPE infection.
Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.
Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
Liver disease in kidney transplant recipients.
Surveillance for CMV infection in orthotopic liver transplant recipients.
Infection with cytomegalovirus is a major cause of morbidity and mortality following orthotopic liver transplantation. In order that preventive strate...
541KB Sizes
0 Downloads
0 Views
Download PDF
Recommend Documents
Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
Association of the Co-stimulatory Molecules Polymorphisms with CMV Infection in Liver Transplant Recipients.
Adenovirus infection in pediatric liver transplant recipients.
Clinical significance of surveillance culture in liver transplant recipients.
Search continues for a CMV vaccine for transplant recipients.
Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
Different behaviour of BK-virus infection in liver transplant recipients.
Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.
Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients.
Hepatitis C viral infection in liver transplant recipients.
×
Sign In
Login with Facebook
Don't have an account?
Forgot Password?
×
Sign Up
By clicking register, I agree to your terms
